Options for the treatment of castration-resistant prostate cancer (CRPC) are severely limited. CRPC is thought to result from augmented activation of the androgen receptor (AR) signalling pathway.

In this study by Shiota and colleagues, heterochromatin protein 1β (HP1β) was found to enhance the DNA-binding ability of AR. In prostate cancer tissues, silencing HP1β suppressed prostate cancer progression and may present a novel therapeutic target. Shiota, M et al (2010) Endocrine-Related Cancer 17.

DOI: 10.1677/ERC-09-0321